PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Corrie, Pippa
TI  - Bevacizumab Monotherapy Improves DFI in Melanoma Patients at High Risk of Recurrence
DP  - 2013 Aug 01
TA  - MD Conference Express
PG  - 16--16
VI  - 13
IP  - 6
4099  - http://mdc.sagepub.com/content/13/6/16.short
4100  - http://mdc.sagepub.com/content/13/6/16.full
AB  - Results of the preplanned interim analysis of the Adjuvant Avastin Trial in High-Risk Melanoma trial [AVAST-M; ISRCTN81261306; EudraCT 2006-005505-64; Corrie P et al. J Clin Oncol 2013 (suppl; abstr LBA9000)] of melanoma patients at high risk of recurrence has shown that adjuvant bevacizumab (BEV) monotherapy is well tolerated and improved disease-free interval. Longer follow-up is required to determine an impact on the primary endpoint of 5-year overall survival.